EU approves six-week dosing schedule for Regeneron's Libtayo
REGN•The European Commission cleared extended dosing and shorter infusions for Regeneron’s Libtayo across six approved skin, lung and cervical cancer indications. Patients can receive 700 mg every six weeks over 30 minutes after 12 weeks of 350 mg every three weeks.




